Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19
Despite effective vaccines and treatments for COVID-19, clinical burden persists. An unmet need exists for additional effective agents with safety profiles allowing use across a broad population. Ibuzatrelvir is an orally bioavailable SARS-CoV-2 Mpro inhibitor that has demonstrated in vitro antivira...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2024-11 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Clinical infectious diseases |
| container_volume | |
| creator | Mortezavi, Mahta Sloan, Abigail Singh, Ravi Shankar P Chen, Luke F Kim, Jin Hyang Shojaee, Negin Toussi, Sima S Prybylski, John Baniecki, Mary Lynn Bergman, Arthur Banerjee, Anindita Allerton, Charlotte Alami, Negar Niki |
| description | Despite effective vaccines and treatments for COVID-19, clinical burden persists. An unmet need exists for additional effective agents with safety profiles allowing use across a broad population. Ibuzatrelvir is an orally bioavailable SARS-CoV-2 Mpro inhibitor that has demonstrated in vitro antiviral activity and low potential for safety concerns, including drug-drug interactions.
This phase 2b, double-blind, randomized clinical trial enrolled US adults aged 18‒ |
| doi_str_mv | 10.1093/cid/ciae529 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3123548748</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3123548748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1299-f4a4a3540e0edd63259f685f9be722b69e0681c2fb15c6c3e04de708670656503</originalsourceid><addsrcrecordid>eNo9kM9LwzAUgIMoTqcn75Kj4KpJ06TJcdRfg-Fg03ksafqqkayZTTuYf72VTQ-P9-B9fIcPoQtKbihR7NbYsh8NPFYH6IRylkaCK3rY34TLKJFMDtBpCJ-EUCoJP0YDphIpiFQnqFzaxjv_bg2eQ1j7OgDWdYkXuoJ2i32FJ0X3rdsG3MY2I6zxs9-Aw4vxfBFlfhnFeFy3tv9pN8K2xuOyc23Ab7b9wNlsObmLqDpDR5V2Ac73e4heH-5fsqdoOnucZONpZGisVFQlOtGMJwQIlKVgMVeVkLxSBaRxXAgFREhq4qqg3AjDgCQlpESKlAguOGFDdLXzrhv_1UFo85UNBpzTNfgu5IzGvV6mfZIhut6hpvEhNFDl68audLPNKcl_s-Z91nyftacv9-KuWEH5z_51ZD-e93Fu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3123548748</pqid></control><display><type>article</type><title>Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Mortezavi, Mahta ; Sloan, Abigail ; Singh, Ravi Shankar P ; Chen, Luke F ; Kim, Jin Hyang ; Shojaee, Negin ; Toussi, Sima S ; Prybylski, John ; Baniecki, Mary Lynn ; Bergman, Arthur ; Banerjee, Anindita ; Allerton, Charlotte ; Alami, Negar Niki</creator><creatorcontrib>Mortezavi, Mahta ; Sloan, Abigail ; Singh, Ravi Shankar P ; Chen, Luke F ; Kim, Jin Hyang ; Shojaee, Negin ; Toussi, Sima S ; Prybylski, John ; Baniecki, Mary Lynn ; Bergman, Arthur ; Banerjee, Anindita ; Allerton, Charlotte ; Alami, Negar Niki</creatorcontrib><description>Despite effective vaccines and treatments for COVID-19, clinical burden persists. An unmet need exists for additional effective agents with safety profiles allowing use across a broad population. Ibuzatrelvir is an orally bioavailable SARS-CoV-2 Mpro inhibitor that has demonstrated in vitro antiviral activity and low potential for safety concerns, including drug-drug interactions.
This phase 2b, double-blind, randomized clinical trial enrolled US adults aged 18‒<65 years with symptomatic COVID-19 and no risk factors for severe disease. Participants were randomized 1:1:2:2 to receive 100, 300, or 600 mg ibuzatrelvir or placebo orally twice daily for 5 days. Nasopharyngeal specimens were collected on Days 1 (baseline), 3, 5, 10, 14, and 21; adverse events (AEs) were recorded through Day 33. The primary endpoint was change in SARS-CoV-2 RNA level (viral load [VL]) from baseline to Day 5 among participants with baseline VL ≥4 log10 copies/mL.
Of 240 enrollees, 237 received ≥1 dose and 199 were included in the primary analysis. Placebo-adjusted least squares mean (80% CI) change from baseline in VL at Day 5 was significant across all doses: 100 mg, ‒0.7 (‒1.1, ‒0.3) log10 copies/mL, P=0.02; 300 mg, ‒0.8 (‒1.3, ‒0.3) log10 copies/mL, P=0.01; and 600 mg, ‒1.2 (‒1.5, ‒0.8) log10 copies/mL, P<0.0001. AEs occurred in similar percentages of participants across groups. No deaths from any cause or treatment-related serious AEs occurred through Day 33, and no participants reported dysgeusia.
All 3 ibuzatrelvir doses were associated with robust antiviral activity and an acceptable safety profile, supporting continued clinical development.
Clinicaltrials.gov identifier: NCT05799495.</description><identifier>ISSN: 1058-4838</identifier><identifier>ISSN: 1537-6591</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciae529</identifier><identifier>PMID: 39486089</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical infectious diseases, 2024-11</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39486089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mortezavi, Mahta</creatorcontrib><creatorcontrib>Sloan, Abigail</creatorcontrib><creatorcontrib>Singh, Ravi Shankar P</creatorcontrib><creatorcontrib>Chen, Luke F</creatorcontrib><creatorcontrib>Kim, Jin Hyang</creatorcontrib><creatorcontrib>Shojaee, Negin</creatorcontrib><creatorcontrib>Toussi, Sima S</creatorcontrib><creatorcontrib>Prybylski, John</creatorcontrib><creatorcontrib>Baniecki, Mary Lynn</creatorcontrib><creatorcontrib>Bergman, Arthur</creatorcontrib><creatorcontrib>Banerjee, Anindita</creatorcontrib><creatorcontrib>Allerton, Charlotte</creatorcontrib><creatorcontrib>Alami, Negar Niki</creatorcontrib><title>Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Despite effective vaccines and treatments for COVID-19, clinical burden persists. An unmet need exists for additional effective agents with safety profiles allowing use across a broad population. Ibuzatrelvir is an orally bioavailable SARS-CoV-2 Mpro inhibitor that has demonstrated in vitro antiviral activity and low potential for safety concerns, including drug-drug interactions.
This phase 2b, double-blind, randomized clinical trial enrolled US adults aged 18‒<65 years with symptomatic COVID-19 and no risk factors for severe disease. Participants were randomized 1:1:2:2 to receive 100, 300, or 600 mg ibuzatrelvir or placebo orally twice daily for 5 days. Nasopharyngeal specimens were collected on Days 1 (baseline), 3, 5, 10, 14, and 21; adverse events (AEs) were recorded through Day 33. The primary endpoint was change in SARS-CoV-2 RNA level (viral load [VL]) from baseline to Day 5 among participants with baseline VL ≥4 log10 copies/mL.
Of 240 enrollees, 237 received ≥1 dose and 199 were included in the primary analysis. Placebo-adjusted least squares mean (80% CI) change from baseline in VL at Day 5 was significant across all doses: 100 mg, ‒0.7 (‒1.1, ‒0.3) log10 copies/mL, P=0.02; 300 mg, ‒0.8 (‒1.3, ‒0.3) log10 copies/mL, P=0.01; and 600 mg, ‒1.2 (‒1.5, ‒0.8) log10 copies/mL, P<0.0001. AEs occurred in similar percentages of participants across groups. No deaths from any cause or treatment-related serious AEs occurred through Day 33, and no participants reported dysgeusia.
All 3 ibuzatrelvir doses were associated with robust antiviral activity and an acceptable safety profile, supporting continued clinical development.
Clinicaltrials.gov identifier: NCT05799495.</description><issn>1058-4838</issn><issn>1537-6591</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kM9LwzAUgIMoTqcn75Kj4KpJ06TJcdRfg-Fg03ksafqqkayZTTuYf72VTQ-P9-B9fIcPoQtKbihR7NbYsh8NPFYH6IRylkaCK3rY34TLKJFMDtBpCJ-EUCoJP0YDphIpiFQnqFzaxjv_bg2eQ1j7OgDWdYkXuoJ2i32FJ0X3rdsG3MY2I6zxs9-Aw4vxfBFlfhnFeFy3tv9pN8K2xuOyc23Ab7b9wNlsObmLqDpDR5V2Ac73e4heH-5fsqdoOnucZONpZGisVFQlOtGMJwQIlKVgMVeVkLxSBaRxXAgFREhq4qqg3AjDgCQlpESKlAguOGFDdLXzrhv_1UFo85UNBpzTNfgu5IzGvV6mfZIhut6hpvEhNFDl68audLPNKcl_s-Z91nyftacv9-KuWEH5z_51ZD-e93Fu</recordid><startdate>20241102</startdate><enddate>20241102</enddate><creator>Mortezavi, Mahta</creator><creator>Sloan, Abigail</creator><creator>Singh, Ravi Shankar P</creator><creator>Chen, Luke F</creator><creator>Kim, Jin Hyang</creator><creator>Shojaee, Negin</creator><creator>Toussi, Sima S</creator><creator>Prybylski, John</creator><creator>Baniecki, Mary Lynn</creator><creator>Bergman, Arthur</creator><creator>Banerjee, Anindita</creator><creator>Allerton, Charlotte</creator><creator>Alami, Negar Niki</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241102</creationdate><title>Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19</title><author>Mortezavi, Mahta ; Sloan, Abigail ; Singh, Ravi Shankar P ; Chen, Luke F ; Kim, Jin Hyang ; Shojaee, Negin ; Toussi, Sima S ; Prybylski, John ; Baniecki, Mary Lynn ; Bergman, Arthur ; Banerjee, Anindita ; Allerton, Charlotte ; Alami, Negar Niki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1299-f4a4a3540e0edd63259f685f9be722b69e0681c2fb15c6c3e04de708670656503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mortezavi, Mahta</creatorcontrib><creatorcontrib>Sloan, Abigail</creatorcontrib><creatorcontrib>Singh, Ravi Shankar P</creatorcontrib><creatorcontrib>Chen, Luke F</creatorcontrib><creatorcontrib>Kim, Jin Hyang</creatorcontrib><creatorcontrib>Shojaee, Negin</creatorcontrib><creatorcontrib>Toussi, Sima S</creatorcontrib><creatorcontrib>Prybylski, John</creatorcontrib><creatorcontrib>Baniecki, Mary Lynn</creatorcontrib><creatorcontrib>Bergman, Arthur</creatorcontrib><creatorcontrib>Banerjee, Anindita</creatorcontrib><creatorcontrib>Allerton, Charlotte</creatorcontrib><creatorcontrib>Alami, Negar Niki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mortezavi, Mahta</au><au>Sloan, Abigail</au><au>Singh, Ravi Shankar P</au><au>Chen, Luke F</au><au>Kim, Jin Hyang</au><au>Shojaee, Negin</au><au>Toussi, Sima S</au><au>Prybylski, John</au><au>Baniecki, Mary Lynn</au><au>Bergman, Arthur</au><au>Banerjee, Anindita</au><au>Allerton, Charlotte</au><au>Alami, Negar Niki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2024-11-02</date><risdate>2024</risdate><issn>1058-4838</issn><issn>1537-6591</issn><eissn>1537-6591</eissn><abstract>Despite effective vaccines and treatments for COVID-19, clinical burden persists. An unmet need exists for additional effective agents with safety profiles allowing use across a broad population. Ibuzatrelvir is an orally bioavailable SARS-CoV-2 Mpro inhibitor that has demonstrated in vitro antiviral activity and low potential for safety concerns, including drug-drug interactions.
This phase 2b, double-blind, randomized clinical trial enrolled US adults aged 18‒<65 years with symptomatic COVID-19 and no risk factors for severe disease. Participants were randomized 1:1:2:2 to receive 100, 300, or 600 mg ibuzatrelvir or placebo orally twice daily for 5 days. Nasopharyngeal specimens were collected on Days 1 (baseline), 3, 5, 10, 14, and 21; adverse events (AEs) were recorded through Day 33. The primary endpoint was change in SARS-CoV-2 RNA level (viral load [VL]) from baseline to Day 5 among participants with baseline VL ≥4 log10 copies/mL.
Of 240 enrollees, 237 received ≥1 dose and 199 were included in the primary analysis. Placebo-adjusted least squares mean (80% CI) change from baseline in VL at Day 5 was significant across all doses: 100 mg, ‒0.7 (‒1.1, ‒0.3) log10 copies/mL, P=0.02; 300 mg, ‒0.8 (‒1.3, ‒0.3) log10 copies/mL, P=0.01; and 600 mg, ‒1.2 (‒1.5, ‒0.8) log10 copies/mL, P<0.0001. AEs occurred in similar percentages of participants across groups. No deaths from any cause or treatment-related serious AEs occurred through Day 33, and no participants reported dysgeusia.
All 3 ibuzatrelvir doses were associated with robust antiviral activity and an acceptable safety profile, supporting continued clinical development.
Clinicaltrials.gov identifier: NCT05799495.</abstract><cop>United States</cop><pmid>39486089</pmid><doi>10.1093/cid/ciae529</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2024-11 |
| issn | 1058-4838 1537-6591 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3123548748 |
| source | Oxford University Press Journals All Titles (1996-Current) |
| title | Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A23%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Virologic%20Response%20and%20Safety%20of%20Ibuzatrelvir,%20a%20Novel%20SARS-CoV-2%20Antiviral,%20in%20Adults%20With%20COVID-19&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Mortezavi,%20Mahta&rft.date=2024-11-02&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciae529&rft_dat=%3Cproquest_cross%3E3123548748%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3123548748&rft_id=info:pmid/39486089&rfr_iscdi=true |